Protease nexin-2/amyloid 6 protein precursor (PN-2/A#PP) is an abundant, secreted platelet protein which is a potent inhibitor of coagulation Factor XIa. We examined other potential anticoagulant activities of PN-2/Ai8PP. Purified Kunitz protease inhibitor domain of PN-2/A8PP and PN-2/ABPP itself were found to prolong the coagulation time of plasma and pure Factor IXa. The Kunitz protease inhibitor domain also inhibited the ability of Factor IXa to activate Factor X. PN-2/AAPP inhibited Factor IXa with a K1 of 7.9 to 3.9 X 10-1 M in the absence and presence of heparin, respectively. When the second-order rate constant of PN-2/AO8PP's inhibition of Factor IXa (2.7 X 108 M-'min-') was compared to that of antithrombin III (3.8 X 106 M-'min-'), PN-2/AfiPP was at least a 71-fold more potent inhibitor of Factor IXa than antithrombin III. PN-2/AfiPP formed a complex with Factor IXa as detected by gel filtration and ELISA. The finding that PN-2/ AfiPP is a potent inhibitor of Factor IXa could help to explain the spontaneous intracerebral hemorrhages seen in patients with hereditary cerebral hemorrhage with amyloidosis Dutchtype where there is an extensive accumulation of PN-2 /A46PP in their cerebral blood vessels. (J. Clin. Invest. 1993.92:2540-2545
Introduction
The amyloid ,B protein precursor (Af3PP)' (1) nile plaques and in the walls of cerebral blood vessels of patients with Alzheimer's disease (2) , and patients with hereditary cerebral hemorrhage with amyloidosis Dutch-type (HCHWA-D) (3, 4) . There are three major isoforms ofAI3PP, two of which contain a domain homologous to Kunitz-type protease inhibitors (KPI) (5) . The secreted isoforms of A#PP containing the KPI domain are analogous to protease nexin-2 (PN-2) (6, 7) . Although the physiologic functions of PN-2/ A3PP
are not yet fully understood, several studies show that PN-2/AI3PP is an abundant platelet a-granule protein that is secreted upon platelet activation (8, 9) and is a potent inhibitor of intrinsic blood coagulation Factor XIa (9, 10) . These findings suggest that PN-2/A,3PP may function as an anticoagulant. Although Factor XI is the first protein of the hemostatic system, clinical states associated with Factor XI abnormalities are usually mild bleeding conditions that occur after trauma but are not spontaneous( 1 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . IfPN-2/ ABPP were aphysiologically important anticoagulant, it would be expected to interact with other proteins of the hemostatic system. Therefore, we sought to determine if PN-2/A#PP influences other proteins of the hemostatic system.
Methods
Proteins. PN-2/A(3PP was purified from fibroblast culture media using techniques of heparin affinity chromatography and immunoaffinity chromatography as previously described ( 10). On nonreduced sodium dodecyl sulfate 10% polyacrylamide gel electrophoresis PN-2/ABPP is a single band at 116 kD; upon reduction, the molecular mass of the protein increased slightly. The KPI domain of PN-2/ABPP was produced in a recombinant yeast expression system and purified as previously described ( 14) . The protease inhibitory activities ofpurified PN-2/Af3PP and KPI domain were determined by titration with active-site titrated trypsin ( 10, 14 
, where E is the Factor IXa concentration, I is the inhibitor concentration, El is the concentration of the enzyme-inhibitor complex, and t is the time of incubation in minutes ( 19) .
Determination ofcomplex formation between Factor IXa and PN-2/AfPP. Sephadex G-l00 (Sigma) gel filtration of Factor IXa (5 mg) or a mixture ofFactor IXa (5 Ag) and PN-2 / AiPP (11 g ) was performed on a 1 x 100 cm column equilibrated in 0.01 M Tris-HCl, 0.15 M NaCl, pH 8.0. The column that was packed freshly upon each use was run on gravity at room temperature at a flow rate of 30 ml/h. Sample size was < 0.03 ml, and 1 -ml fractions were collected. The void volume was determined by gel filtration ofblue dextran (Sigma Chemical Co.). Molecular mass markers of human immunoglobulin G ( 160 kD) and bovine serum albumin (68 kD) were used to characterize the column. Column fractions were assayed for Factor IXa antigen by ELISA. 0. 
Results
Initial investigations were performed to determine ifa purified, recombinant KPI domain of PN-2 /ABPP inhibited the coagulant activity of normal human plasma (Fig. 1 A) . KPI domain at 1 MM prolonged the APTT more than twofold over pooled normal plasma. When the ability of recombinant KPI domain to inhibit the coagulant activity of pooled normal human plasma was compared to purified whole PN-2/A3PP, which was only available at concentrations < 200 nM, KPI domain was found to be a more potent inhibitor ofthe coagulant activity of plasma than PN-2 / APP (Fig. 1 A) . Since PN-2 /AI3PP
and its KPI domain are potent inhibitors of Factor XIa, the prolongation ofthe APTT could simply be explained by inhibition of this enzyme alone.
To determine if the prolongation of the APTT was simply caused by the KPI domain ofPN-2 / AJPP inhibiting the coagulant activity of Factor XIa, specific coagulation factor assays were performed for each of the coagulation enzymes below the level of Factor XIa in the hemostatic cascade (Fig. 1 B) . As previously reported for an enzymatic assay (9, 10) (Fig. 2 B) . These studies indicated that the KPI domain of PN-2/Af3PP is an inhibitor of Factor IXa, as well as Factor XIa. Both the KPI domain and PN-2/Af3PP inhibited Factor IXa's ability to activate Factor X in concentrations less than 10-fold molar excess within 10 min. The stoichiometry of active-site titrated Factor IXa to PN-2 /Af3PP was 1.3 to 1.0. The Km of Factor IXa activation of Factor X in this assay was 2.08 1tM as determined by a double reciprocal plot. Equilibrium inhibition constants (Ki) were determined to be 7.9 X 10-" and 3.9 x 10-" M for the inhibition of Factor IXa by PN-2/ ABPP in the absence and presence ofheparin, respectively (Table I). The present findings with Factor IXa are similar to the equilibrium inhibition constants previously described for inhibition ofFactor XIa by PN-2/AI3PP (9, 10). Alternatively, a Ki of 1.9 x 10-7 M was obtained for the inhibition of Factor IXa by the purified KPI domain suggesting that regions outside the KPI domain may be important for optimum inhibition ofFactor IXa by PN-2/AfAPP. The second-order association rate constants (K..) for Factor IXa and the KPI domain or PN-2/ A#PP were determined for comparison to the K__ for Factor IXa and antithrombin III, the major plasma inhibitor ofFactor IXa (20) . The KPI domain itself had a K__ of 6.9 X I0 1 M-'min-'; however, in this assay purified PN-2/Af3PP was a 400-fold faster acting inhibitor of Factor IXa with K__ of 2.7 X 108 M-'min'- (Table I ). The addition of heparin ( 1 U/ml) increased the rate of Factor IXa inhibition less than twofold with a K__ of 3.6 X 108 M min-'. PN-2/ABPP in the absence or presence of heparin was a 71-fold or 95-fold, respectively, more potent inhibitor of Factor IXa than antithrombin III in the presence of heparin (K, = 3.8 x 106 M-'min-').
To confirm that PN-2/AflPP associated with Factor IXa to inactivate it, investigations were performed to determine if complex formation occurred between Factor IXa and PN-2/ A(3PP (Fig. 3) . Purified immunoglobulin G and blue dextran (data not shown) gel filtered identically at fraction 32, characterizing the void volume of the column (Fig. 3 A) . Bovine serum albumin gel filtered at fraction 38. Purified Factor IXa antigen gel filtered as a broad peak between fractions 40 and 58. This finding indicated that Factor IXa alone did not gel filter as a void volume protein on this column. When Factor IXa was incubated with purified PN-2/A(3PP, a portion of the total Factor IXa antigen appeared in a new broad peak between fractions 32 and 39 (Fig. 3 B) . These data indicated that some of the Factor IXa formed a higher molecular mass complex with the purified PN-2/ABPP. Further studies were performed to determine if Factor IXa forms a complex with PN-2 /Aj3PP as detected by ELISA (Fig. 4) . When Factor IXa was incubated with PN-2/ABPP linked to microtiter plate wells, Factor IXa was detected specifically bound to the PN-2/A3PP. (30) . The selective accumulation of PN-2/A PP in the cerebral vessels of HCHWA-D patients could result in decreased Factor IXa activity, leading to the spontaneous intracerebral hemorrhages characteristic of this disorder (3, 4) .
